Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer

BACKGROUND: Pemetrexed plus platinum alone is the conventional first-line therapy for locally advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable genetic aberrations. The ORIENT-11 trial revealed that sintilimab + pemetrexed plus platinum could yield more survival b...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yafei, Qian, Di, Li, Yanhui, Chen, Wei, Bo, Mingming, Zhang, Mingyu, Shi, Jianglei, Jia, Bei, Dai, Yuanyuan, Li, Guohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175008/
https://www.ncbi.nlm.nih.gov/pubmed/37180653
http://dx.doi.org/10.21037/tcr-22-2030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175008/
https://www.ncbi.nlm.nih.gov/pubmed/37180653
http://dx.doi.org/10.21037/tcr-22-2030

Ejemplares similares